Review Article

Strategies to Enhance Mesenchymal Stem Cell-Based Therapies for Acute Respiratory Distress Syndrome

Jibin Han,1 Yanmin Li,2 and Yuanyuan Li1

1Department of Critical Care Medicine, First Hospital of Shanxi Medical University, No. 85, Jiefangnan Road, Taiyuan, 030001 Shanxi, China
2Department of Anesthesiology, First Hospital of Shanxi Medical University, No. 85, Jiefangnan Road, Taiyuan, 030001 Shanxi, China

Correspondence should be addressed to Yuanyuan Li; yuana_4685@sina.com

Received 28 July 2019; Accepted 28 October 2019; Published 22 November 2019

Academic Editor: Antonio C. Campos de Carvalho

Copyright © 2019 Jibin Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute respiratory distress syndrome (ARDS) is a multifaced disease characterized by the acute onset of hypoxemia, worsened pulmonary compliance, and noncardiogenic pulmonary edema. Despite over five decades of research, specific treatments for established ARDS are still lacking. MSC-based therapies have the advantage of targeting nearly all pathophysiological components of ARDS by means of a variety of secreted trophic factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. However, the therapeutic efficacy of transplanted MSCs is limited by their poor engraftment and low survival rate in the injured tissues, major barriers to clinical translation. Accordingly, several strategies have been explored to improve MSC retention in the lung and enhance the innate properties of MSCs in preclinical models of ARDS. To provide a comprehensive and updated view, we summarize a large body of experimental evidence for a variety of strategies directed towards strengthening the therapeutic potential of MSCs in ARDS.

1. Introduction

ARDS is a catastrophic disease characterized by acute onset of hypoxic respiratory failure, noncardiogenic pulmonary edema, and decreased pulmonary compliance, which can subsequently trigger a cascade of serious complications and even progress to multiple organ failure. ARDS can result from various causes, including sepsis, multiple trauma, massive blood transfusion, pneumonia, aspiration, pulmonary contusion, and cardiopulmonary bypass. Abundant protein-rich fluid accumulated in the alveolar space due to diffuse alveolar-capillary barrier damage is the most prominent pathophysiological feature of patients with ARDS. Although comprehensive research has enabled clinicians to gain deep insight into the complex pathogenesis of ARDS, its incidence is still increasing [1]. The period prevalence of ARDS is 10.4% for patients admitted to ICUs, and the hospital mortality of patients with mild, moderate, and severe ARDS is 34.9%, 40.3%, and 46.1%, respectively [2]. Even though more patients are surviving ARDS due to advances in intensive care, these survivors of ARDS commonly suffer new or worsening brain dysfunction, cognitive impairment, anxiety symptoms, and physical limitations as well as increased readmission risk after hospital discharge in the following years, imposing substantial costs on the public health system [3].

Despite fifty years of research, there is still no specific therapy for ARDS. To date, therapeutic options remain confined to supportive care, including protective mechanical ventilation, prone-positioning ventilation, and fluid-conservative strategy. It is well established that mechanical ventilation with a lower tidal volume shortened the duration of mechanical ventilation and significantly decreased 28-day mortality [4]. Furthermore, early application of prolonged prone-positioning sessions significantly decreased 28-day and 90-day mortality for patients with severe ARDS [5]. However, mechanical ventilation carries a high risk for developing ventilation-induced lung injury (VILI) due to
epithelial strain and stress from inhomogeneously injured lungs, and in turn, VILI exacerbates lung injury and stimulates an inflammatory reaction [6, 7]. Venovenous extracorporeal membrane oxygenation (VV-ECMO) is potentially a life-saving intervention to rescue patients with ARDS while avoiding overstretching the injured lungs [8], but nevertheless, the routine application of ECMO as a salvage therapy in patients with severe ARDS is still controversial [9]. Although early short-term use of a neuromuscular blockade in moderate to severe ARDS improved survival rates by decreasing markers of epithelial and endothelial injury and systemic inflammation [10], a variety of pharmacological therapies, including statins, aspirin, antioxidants, inhaled corticosteroids, beta-2 agonists, surfactants, and other anti-inflammatory drugs, have failed to show benefit [11]. To circumvent potential life-threatening complications and minimize the risk of mortality following ARDS, alternative therapeutic measures are urgently required to ameliorate lung injury and promote lung repair.

Theoretically, cell-based therapy can target multiple aspects of the pathophysiology underlying ARDS and may become a new kind of clinical therapy. Over recent years, cell therapy has been introduced in preclinical ARDS studies. A variety of cell types have been examined as promising candidates for potential therapeutic use, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), pulmonary epithelial progenitor cells (EpPCs), and endothelial progenitor cells (EnPCs) [12]. Among these cell types, MSCs, also referred to as mesenchymal stromal cells, are of considerable interest as a potential candidate for the treatment of ARDS [13].

2. Mechanisms of MSCs in Treating ARDS

MSCs were initially isolated from the bone marrow by Friedenstein and his colleagues in the 1970s [14]. The minimum criteria for defining human MSCs proposed by the International Society for Cellular Therapy (ISCT) must meet the following requirements: MSCs are a plastic adherent cell; express cell surface marker of CD105, CD73, and CD90 and absence of CD45, CD34, CD14, and HLA-DR; and also, with the capacity to differentiate to osteoblasts, chondrocytes, and adipocytes under the appropriate condition [15, 16]. Apart from the bone marrow, MSCs can be harvested from a variety of sources, including adipose tissues and umbilical cord blood [17, 18]. A lot of studies show that the level of injected MSCs that differentiate into tissue-appropriate phenotypes is very low [19–21]. Increasing evidence support the notion that MSCs promote tissue recovery and regeneration via secreting a variety of paracrine factors, conferring anti-inflammatory, immunomodulatory, angiogenic, antiinfective, antimicrobial, and structural reparative properties [22, 23]. Notably, MSCs possess an immunomodulatory property via inhibiting T cell proliferation and regulating B cell functions, as well as the ability to suppress the maturation of dendritic cells [24]. Furthermore, MSCs were shown to reprogram macrophages by secreting prostaglandin E2 to increase interleukin-10 production in a septic lung model [25]. Of additional interest, Islam et al. revealed that the mechanism behind the protective effect of MSCs against lung injury involved mitochondrial transfer to pulmonary alveoli [26].

3. Obstacles to Clinical Translation

Given that MSC-based therapy offers great promise in preclinical ARDS models, several phase I/II clinical trials have been conducted to assess the safety of human MSC injections in patients with ARDS. The study performed by Zheng et al. showed that no serious adverse events related to MSC administration were observed in twelve patients with ARDS [27]. Moreover, Wilson et al. also demonstrated that intravenous administration of MSCs was well tolerated in nine patients with moderate to severe ARDS [28]. Simonson et al. administered MSCs to two patients with severe ARDS and found that both patients demonstrated improved lung function and resolution of multiorgan failure [29]. Recently, the START study demonstrated that no hemodynamic or respiratory adverse events related to MSC infusion were observed over a 60-day follow-up period and the 28-day mortality was numerically higher in the MSC group than in the placebo but did not differ significantly between groups [30]. It is worth noting that the tendency toward harm in the START study may be attributed to the imbalances in the severity of illness and the wide variability in MSC viability. The completed clinical studies regarding the treatment of ARDS with MSCs were summarized in Table 1. Thus, there is an urgent need to advance the modest efficacy of MSCs observed in clinical trials. In addition, low mobilization of MSCs to the sites of injury and poor survival of transplanted MSCs in the harsh microenvironment are obstacles faced by clinical translation. Accordingly, several strategies have been explored to improve MSC retention in the lung and enhance the innate properties of MSCs in the preclinical model of ARDS (Figure 1).

4. Genetic Modification to Enhance MSC Potency

The strategy using genetic modification focusing on transfecting MSCs with beneficial genes has attracted the attention of researchers for its multiple advantages, not only enhancing the intrinsic ability of MSCs to migrate to the site of damage and facilitate tissue repair but also improving the capability of MSCs to survive in the harsh microenvironments. The candidate genes tested in preclinical ARDS models are summarized in Table 2.

5. Chemokine Receptor 4

Stromal-derived factor-1 (SDF-1) with its unique chemokine receptor 4 (CXCR4) has been found to play a vital role in directing the migration of MSCs. However, only a small portion of MSCs express CXCR4, and CXCR4 expression on the surface of MSCs significantly declined in the process of...
| Study title                                                                 | The number of included patients | MSC source                             | MSC dose                                   | Outcomes                                                                                       | Significance                                                                                                                                                                                                                                                                                                | Reference |
|---------------------------------------------------------------------------|---------------------------------|----------------------------------------|--------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study | 12                              | MSCs derived from adipose of a healthy female donor | One dose; $1 \times 10^6$ cells/kg          | (i) No patient suffered clinical complications related to cell infusion                        | (ii) No significant differences regarding PaO$_2$/FiO$_2$ and SP-D, IL-6, or IL-8 levels were observed between the MSC group and the placebo group                                                                                                                                                                                                                   | [27]      |
| Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial | 9                               | MSCs derived from the bone marrow of a healthy male donor | One dose; three patients received $1 \times 10^6$ cells/kg PBW; three patients received $5 \times 10^6$ cells/kg PBW; three patients received $10 \times 10^6$ cells/kg PBW | (i) No infusion-related events or treatment-associated adverse events were observed              | (ii) The LIS and SOFA score were lower in the high-dose group, but did not differ significantly compared with both reduced doses                                                                                                                                                                                                                                        | [28]      |
| In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome | 2                               | MSCs derived from the bone marrow of a healthy male donor | One dose; $2 \times 10^6$ cells/kg          | (i) A reduction in multiple pulmonary and systemic markers of inflammation                   | (ii) Both patients demonstrated improved lung function                                                                                                                                                                                                                                                                                                                  | [29]      |
| Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomized phase 2a safety trial | 60                              | Allogeneic MSCs derived from human bone marrow | One dose; $10 \times 10^6$ cells/kg PBW      | (i) No infusion-related hemodynamic or respiratory adverse events were observed               | (ii) Mortality was higher in the MSC group than in the placebo, but did not differ significantly between groups                                                                                                                                                                                                                                                        | [30]      |

LIS: lung injury score; SOFA: Sequential Organ Failure Assessment; PBW: predicted bodyweight; SP-D: serum surfactant-associated protein-D; IL-6: interleukin-6; IL-8: interleukin-8.
multiple ex vivo expansions. Low expression of CXCR4 in MSCs may account for their low efficiency in homing to damaged tissues, which limits the therapeutic effect. Yang et al. introduced CXCR4 into bone marrow MSCs via a lentiviral vector and showed that CXCR4 overexpression dramatically improved the chemotactic properties of MSCs in vitro [31]. Using a rat model of ALI induced by lipopolysaccharide (LPS), they also found that CXCR4 facilitated MSC homing to and colonization of injured lung tissues, and furthermore, CXCR4-MSCs offered an additional protective effect of attenuating LPS-induced ALI in rats [31].

6. E-Prostanoid 2 Receptor

Prostaglandin E2 (PGE2) is a vital inflammatory cytokine, and its biosynthesis is significantly increased in the inflammatory microenvironment. In particular, PGE2 promotes the migration of MSCs through activation of the E-prostanoid 2 (EP2) receptor in vitro [32]. Accordingly, it is apparently reasonable that PGE2 could be deemed a chemokine to facilitate the migration of MSCs by activating the EP2 receptor. Han et al. observed that PGE2 production markedly increased in the damaged lung tissues following LPS challenge [33]. In addition, they transduced the bone marrow-derived MSC-based EP2 gene by lentiviral vectors and tested their effects in a mouse model of LPS-induced ALI. Their results demonstrated that MSCs transfecting with EP2 significantly facilitated the mobilization of MSCs to sites of lung injury and, furthermore, ameliorated both pulmonary inflammation and permeability [33].

7. Heme Oxygenase-1

Heme oxygenase-1 (HO-1) is a stress-response protein with antiapoptotic, anti-inflammatory, and antioxidative properties, protecting cells from injury and restoring homeostasis in various pathologic states. When using a Transwell system to coculture pulmonary microvascular endothelial cells (PVECs) injured by LPS and MSCs transfected with the HO-1 gene, the authors reported that HO-1-MSCs exerted an enhanced capacity to ameliorate LPS-induced inflammatory and oxidative damage in PVECs [34]. Chen et al. further tested the curative effects of bone marrow-derived MSCs overexpressing HO-1 via lentiviral vectors in the LPS-induced ALI rat model [35]. They demonstrated that HO-1-MSCs ameliorated cytokine levels in serum, the neutrophil counts and total protein concentration in bronchoalveolar lavage fluid, and the histological changes in the lung to a greater extent than unmodified MSCs [35].

8. Angiotensin-Converting Enzyme 2

Mounting evidence has suggested that angiotensin-converting enzyme 2 (ACE2) plays a prominent role in the physiological and pathological processes of the respiratory systems [36]. Intriguingly, ACE2 was reported to protect against lung injury by degrading the profibrotic peptide angiotensin (Ang) II [37]. Bone marrow-derived MSCs overexpressing the ACE2 gene via lentiviral vectors were demonstrated to have an enhanced ability to alleviate endothelial injury resulting from LPS stimulation [38]. He et al. demonstrated that the administration of
ACE2-MSCs offered additional anti-inflammatory and endothelial-protective effects against LPS-induced lung injury in mice [39]. Furthermore, the study performed by Min et al. showed that MSCs and ACE2 had a synergistic therapeutic effect on bleomycin-induced ALI [40].

**9. Hepatocyte Growth Factor**

Hepatocyte growth factor (HGF), which was initially thought to be a potent mitogen for hepatocytes, is a candidate for boosting angiogenesis, engraftment, anti-inflammation, and antifibrosis due to its pleiotropic effect. Using a BALB/c mouse model of bronchiolitis obliterans, Cao et al. demonstrated that HGF-modified MSCs improved histopathological and biochemical markers in the recovery of allograft tracheal histopathology [41]. Notably, Wang et al. suggested that HGF-modified bone marrow MSCs offered incremental benefits in radiation-induced ALI mice [42]. When compared with MSCs alone, HGF-MSCs significantly decreased the secretion and expression of proinflammatory cytokines as well as reduced the levels of profibrosis factors, while they markedly increased the expression of the anti-inflammatory cytokine interleukin-10 (IL-10) [42].

### Table 2: Genetic modification to enhance MSC potency in ARDS preclinical model.

| Candidate gene | ARDS preclinical model | MSC source/delivery route | Effects                                                                 | Reference |
|----------------|------------------------|---------------------------|-------------------------------------------------------------------------|-----------|
| CXCR4          | Rat model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Facilitate homing of MSCs to damaged lung tissue<br>(ii) Enhance MSC inhibition of lung injury<br>(iii) Enhance the inhibition of lung tissue inflammation | [31]      |
| EP2            | Murine model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Improve MSC retention in the lung<br>(ii) Reduce LPS-induced pulmonary vascular permeability<br>(iii) Improve lung histopathology | [33]      |
| HO-1           | Rat model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Attenuate LPS-induced lung injury<br>(ii) Increase the levels of HGF, KGF, and IL-10<br>(iii) Improve 7-day survival rate | [35]      |
| ACE2           | Murine model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Improve lung histopathology<br>(ii) Alleviate LPS-induced lung and systemic inflammation<br>(iii) Improve pulmonary endothelial functions | [39]      |
| HGF            | Mouse model of radiation-induced lung injury | Bone marrow/tail vein injection | (i) Attenuate histopathological changes<br>(ii) Improve lung permeability<br>(iii) Reduce secretion and expression of proinflammatory cytokines | [42]      |
| Ang1           | Murine model of LPS-induced ALI | Bone marrow/jugular vein injection | (i) Improve lung histopathology<br>(ii) Attenuate the increase in MPO activity<br>(iii) Reduce neutrophil cell count in BALF | [45]      |
| sST2           | Murine model of LPS-induced ALI | Adipose tissue/tail vein injection | (i) Attenuated pulmonary inflammation<br>(ii) Decreased apoptosis and necrosis of bronchial tissue | [47]      |
| IL-10          | Mouse model of endotoxin-induced ALI | Bone marrow/intratracheal injection | (i) Promote better survival in ALI mice<br>(ii) Reduce BALF protein level<br>(iii) Result in sustained enrichment of serum IL-10 and IL-10-expressing T cells | [49]      |
| MnSOD          | Mouse model of radiation-induced ALI | Bone marrow/tail vein injection | (i) Improved survival and lung histopathology injury<br>(ii) Alleviate lung inflammation<br>(iii) Exert antifibrotic effect | [51]      |
| KGF            | Mouse model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Reduce lung wet/dry ratio<br>(ii) Improve lung inflammation<br>(iii) Improve lung histopathology and survival | [54]      |
| Del-1          | Mouse model of LPS-induced ALI | Bone marrow/tail vein injection | (i) Reduce lung wet/dry ratio<br>(ii) Attenuate the increase in MPO activity<br>(iii) Alleviate lung inflammation | [56]      |

ARDS: acute respiratory distress syndrome; ALI: acute lung injury; LPS: lipopolysaccharide; CXCR4: chemokine receptor 4; EP2: E-prostanoid 2 receptor; HO-1: heme oxygenase-1; ACE2: angiotensin-converting enzyme 2; HGF: hepatocyte growth factor; Ang1: angiopoietin-1; sST2: soluble IL-1 receptor-like-1; IL-10: interleukin-10; MnSOD: manganese superoxide dismutase; KGF: keratinocyte growth factor; BALF: bronchoalveolar lavage fluid; MPO: myeloperoxidase; Del-1: developmental endothelial locus-1.
10. Angiopoietin-1

Angiopoietin-1 (Ang1), an angiogenic growth factor, acts as a crucial regulator of angiogenesis, vascular stabilization, and anti-inflammatory actions by improving vascular permeability and inhibiting leukocyte-endothelium interactions [43]. In a mouse model, the combination of MSC and Ang1 gene therapy exhibited a synergistic effect on alleviating LPS-induced lung injury, as reflected by improvement in the histopathological and biochemical indices [44]. In line with previous research, treatment with Ang1-MSCs resulted in a further improvement in both the recruitment of inflammatory cells into the lung and pulmonary vascular endothelial permeability compared with administration of MSCs alone [45]. These findings demonstrate a potential role for MSC-based Ang1 therapy in managing patients with ARDS.

11. Soluble IL-1 Receptor-Like-1

Interleukin-33 (IL-33), the newest member of the IL-1 family, is produced in response to endothelial and epithelial injury. The axis of IL-33 and its receptor soluble IL-1 receptor-like-1 (sST2) participates in the stimulation and amplification of immunoregulatory and anti-inflammatory responses. Of note, sST2 has been suggested to function as a negative regulator of LPS-induced proinflammatory factor production by acting directly on macrophages through inhibition of the Toll-like receptor 4 expression [46]. Martínez-González et al. engineered adipose-derived MSCs overexpressing sST2 via lentiviral transfection and applied sST2-MSCs in a murine model of LPS-induced ALI [47]. In their study, MSCs overexpressing sST2 afforded a superior therapeutic effect on the detrimental immune-inflammatory response occurring in ALI.

12. Interleukin-10

IL-10 is an anti-inflammatory factor with vital immunoregulation effects. IL-10 expression is severely reduced in mice suffering from ALI, and a strategy aimed at increasing the level of IL-10 in the local microenvironment might alleviate lung injury. Kapur et al. demonstrated that an inhibitory response mediated by both T regulatory cells (Tregs) and dendritic cells (DCs) defended against transcription-related ALI via IL-10. Furthermore, IL-10 administration fully prevented and rescued lung injury in mice [48]. Intriguingly, Wang et al. demonstrated that administration of MSCs overexpressing IL-10 resulted in a significantly higher IL-10 concentration in serum compared to direct IL-10 injection, thereby inducing a series of positive regulatory effects associated with inflammatory reactions and facilitating the survival of endotoxin-induced ALI in a mouse model [49].

13. Manganese Superoxide Dismutase

Manganese superoxide dismutase (MnSOD) is a crucial member of the superoxide dismutase (SOD) family that detoxifies reactive oxygen species (ROS), thereby protecting the cells against the detrimental effect of oxidative stress. It is important to note that administration of MnSOD-plasmid/liposome complexes ahead of irradiation-induced lung injury can alleviate the injury caused by acute or chronic irradiation [50]. In mouse models of radiation-induced lung injury (RILI), systemic administration of bone marrow-derived MSCs overexpressing MnSOD via lentiviral transfection markedly reduced oxidative stress, ameliorated lung inflammation, attenuated pulmonary fibrosis, improved histopathologic changes, and protected the lung cells from apoptosis [51].

14. Keratinocyte Growth Factor

Keratinocyte growth factor (KGF), a paracrine cytokine belonging to the fibroblast growth factor (FGF) family, is significantly upregulated following epithelial damage, suggesting that it has a vital role in tissue repair [52]. Increasing evidence has shown that KGF can protect lung tissues from oxidative insults and facilitate the regeneration of type II alveolar epithelial cells by acting on a subset of FGF receptor isoforms, thereby maintaining the integrity of the alveolar barrier [53]. Interestingly, Chen et al. demonstrated that MSC-based KGF gene therapy not only ameliorated pulmonary microvascular permeability but also attenuated proinflammatory responses in a mouse model of ALI induced by LPS [54]. The synergistic effects of KGF-MSCs on lung injury may be ascribed to the stimulation of type II alveolar cell proliferation.

15. Developmental Endothelial Locus-1

Developmental endothelial locus-1 (Del-1) is an endothelial-secreted anti-inflammatory molecule that inhibits inflammatory cell recruitment and the integrin lymphocyte function-associated antigen-1-dependent leukocyte-endothelial adhesion [55]. Del-1-overexpressed MSCs were established via lentiviral vectors and administered into mice of ALI injured by LPS through the tail vein; researchers found that the administration with Del-1-overexpressed MSCs offered incremental benefits on LPS-induced ALI [56]. There was a marked reduction in the serum levels of IL-6 and TNF-α and the number of neutrophils in BAL in the ALI mice treated with MSCs carrying Del-1. Moreover, lower lung injury scores and a higher myeloperoxidase activity were observed in the mice treated with Del-1-expressed MSCs than in the mice treated with MSCs alone.

16. The Limitations of Genetic Modification

Owing to its high transfection efficiency, viral transfection is the most common method used for genetic modification. However, there are several drawbacks to viral transfection. Firstly, viral transfection has the risk of triggering oncogenes during the transgene procedure; thus, it may lead to tumorigenesis [57]. Secondly, viral vectors may evoke antigenspecific adaptive immune responses which can scavenge therapeutic gene products and transfected MSCs [58], ultimately limiting the therapeutic efficacy. Thirdly, it usually takes weeks or months to establish genetically modified...
and other tissues is hypoxic, ranging from 1% to 12% O₂. Biological oxygen tension in the bone marrow environment cannot mimic the in vivo hypoxic environment. The physiology of MSCs and exerts a pivotal role in the beneficial effects of MSC administration. The soluble factor profile of MSCs is extremely affected by the local microenvironment surrounding the cells, and some trophic cytokines are considerably upregulated in response to pathological stimulation [62]. Hypoxic culture triggers MSCs to secrete an abundance of soluble factors, including VEGF, Ang1, HGF, IGF-1, and bFGF-2, which are bioactive molecules associated with proangiogenic, antiapoptotic, and antioxidative effects [63, 64]. In a bleomycin-induced pulmonary fibrotic mouse model, the administration of hypoxia-preconditioned MSCs significantly downregulated the levels of inflammatory and fibrotic factors in the lung tissues and attenuated the degree of lung fibrosis [65]. These observed benefits were partially attributed to the upregulation of the hepatocyte growth factor under hypoxic conditions.

Mounting evidence suggests that pretreatment with hypoxia facilitates migration of MSCs by upregulating the level of SDF-1 as well as stimulating CXCR4 expression [66]. Short-term culture of MSCs under 1% oxygen upregulated the mRNA and protein of CXCR4 [67]. In line with these findings, hypoxic preconditioning evoked MSCs to express high levels of CXCR4 and CXCL12, the receptors of the chemokine stromal-derived factor-1 (SDF-1), by activating hypoxia-inducible factor-1 (HIF-1α), thereby improving the adhesion and engraftment of MSCs in the target tissue [68]. Consequently, optimizing the oxygen concentration prior to MSC administration should be deemed a novel strategy to enhance their engraftment in vivo.

Hypoxia preconditioning combined with MSC transplantation to achieve increased therapeutic effects has been extensively tested in a number of preclinical disease models, including brain ischemia, myocardial infarction, and acute kidney injury [69–71]. Treatment with hypoxia-preconditioned MSCs extended the duration of survival of engrafted cells, improved pulmonary respiratory functions, downregulated inflammatory and fibrotic factor expression, and alleviated histological changes in a bleomycin-induced pulmonary fibrosis mouse model [65]. Liu et al. investigated the therapeutic impact of hypoxia-preconditioned MSCs on ischemia/reperfusion (I/R) lung injury in a rat

**Table 3: Different preconditioning strategies to improve MSC efficacy in the ARDS preclinical model.**

| Preconditioning | ARDS preclinical model | MSC source/delivery route | Effects | Reference |
|-----------------|------------------------|---------------------------|---------|-----------|
| Hypoxia         | Rat model of ischemia/reperfusion-induced lung injury | Rat bone marrow/administration in the circulating perfusate into pulmonary artery | (i) Reduce lung weight gain and the ratio of wet weight/dry weight (ii) Decrease white cell count in BALF (iii) Reduce level of MPO in the lung tissue | [72] |
| Serum from ARDS patients | Murine model of LPS-induced ARDS | Human bone marrow/ intravenous injection | (i) Reduce BALF inflammatory cells (ii) Increase plasma IL-10 (iii) Decrease TNF and IL-1 | [74] |
| NAC             | Mice model of bleomycin-induced lung injury | Human embryo/tail vein injection | (i) Reduce inflammation and fibrosis in the injured lung (ii) Reduction of apoptosis in lung cells (iii) Reducing the mortality of mice with bleomycin-induced lung injury | [75] |
| TGF-β1          | Rat model of LPS-induced ALI | Human umbilical cord/tail vein injection | (i) Attenuate LPS-induced systemic injury (ii) Increase MSC survival in damaged lungs | [76] |

ARDS: acute respiratory distress syndrome; ALI: acute lung injury; LPS: lipopolysaccharide; NAC: N-acetylcysteine; TGF-β: transforming growth factor-β; BALF: bronchoalveolar lavage fluid; MPO: myeloperoxidase; IL-10: interleukin-10; IL-1: interleukin-1.
model and found that hypoxic MSCs quickly moved towards injured lung tissues and mitigated pulmonary damage through anti-inflammatory, antiapoptotic, and antioxidant mechanisms [72].

19. Serum from ARDS Patients

Recently, the study performed by Islam et al. found that distinct proteomic profiles were observed in different stages of lung injury, and the lung microenvironment is a crucial determinant of effective MSC therapy in ALI [73], highlighting the significance of taking into account MSC-microenvironment interactions when applying MSC therapy in ARDS. MSCs activated with a pool of serum obtained from patients with ARDS led to increased IL-10 and interleukin-1 receptor antagonist (IL-1RN) expression, thus improving the protective anti-inflammatory capacity of MSCs compared with nonactivated cells [74]. In a murine model of ARDS, administration of these ARDS serum-preactivated MSCs was more effective in reducing lung injury score, attenuating pulmonary edema, and alleviating inflammatory cell accumulation compared with control MSCs [74].

20. N-Acetylcysteine

N-Acetylcysteine (NAC) is a precursor of glutathione and has antioxidative action against the toxic effects of reactive oxygen species (ROS) by scavenging free radicals and conferring substrates to activate antioxidant enzymes. Wang et al. demonstrated that NAC preconditioning can restore cellular redox balance by eliminating ROS and increasing glutathione levels when MSCs are exposed to oxidative stresses in vitro [75]. Furthermore, NAC pretreatment strengthened the therapeutic effect of the transplanted MSCs in a mouse model of bleomycin-induced lung injury. MSCs pretreated with NAC were more effective than control cells at improving the engraftment and survival rate of MSCs in injured lung tissue while reducing the pathological grade of pulmonary inflammation and fibrosis [75].

21. Transforming Growth Factor-β1

The chemotaxis and homing of MSCs in vivo are critical to the local microenvironment, particularly the extracellular matrix (ECM), which may enable MSC survival and expansion. Li et al. demonstrated that pretreatment of MSCs with low levels of TGF-β1 resulted in increased expression of fibronectin, which is a major component of ECM [76]. To further explore whether pretreatment with a low concentration of transforming growth factor-β1 (TGF-β1) was favorable for MSC survival in vivo, a rat model of LPS-induced ALI was generated, and the results showed that an increased number of MSCs were observed in the lung 2 weeks following transplantation, indicating that TGF-β1-treated MSCs may enhance their long-term therapeutic effect when applied to tissue repair [76].

22. Three-Dimensional Culture

Cultivation of MSCs in a three-dimensional (3D) microenvironment is a novel preconditioning strategy to replicate the physiological or pathological milieu where the cells would reside following transplantation [77]. Bartosh et al. suggested that the 3D culture of MSCs in spheroids was more effective than MSCs from adherent cultures in attenuating neutrophil activity and reducing proinflammatory cytokines in a mouse model of peritonitis, indicating that MSC culture in a 3D condition is a promising approach for diseases featuring unresolved inflammation [78]. Other studies found that adipose-derived stem cells exposed to short-term spheroid formation before the monolayer culture exhibited superior regenerative potential by improving their chemotaxis, angiogenesis, and stemness properties, thus enhancing their repair capacity for clinical application [79].

23. Other Preconditioning Strategies to Increase MSC Potency

There are also a variety of preconditioning strategies that have been tested in other disease models. Pioglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ), is known to trigger metabolism of mitochondrial free fatty acid, which is a major energy source for cardiomyocytes. Administration of pioglitazone-pretreated MSCs significantly improved efficiency of cardiomyogenesis and cardiac function as evidenced by echocardiogram and immunohistochemistry results [80]. Pretreatment of MSCs with tetrandrine prior to transplantation can significantly enhance the immunomodulatory efficacy. In a mouse ear skin inflammation model, systemic administration of tetrandrine-pretreated MSCs markedly attenuated the level of TNF-α in the inflamed ear, compared to unpretreated MSCs [81]. These precondition strategies might be promising for increasing MSC potency in the management of ARDS.

24. Other Strategies to Optimize MSC Therapy

MSCs gradually lose their initial morphology and multipledifferentiation ability over time. In addition, long-term culture will result in abnormal changes to DNA, RNA, and protein in MSCs [82]. After more than 15 passages, both the proliferation and the bone formation ability of MSCs are significantly reduced. Additionally, the chemokine receptors and paracrine cytokines expressed by aged MSCs are markedly decreased, which in turn attenuates MSCs’ migration capacity and pleiotropic properties [83]. Now, it is believed that the proliferation capacity, paracrine signaling, differentiation potential, and DNA stability of MSCs within five serial passages are all maintained in relatively good condition and that such MSCs may achieve better therapeutic effects when applied to patients with ARDS than aged MSCs.

Recently, Islam et al. demonstrated that the lung microenvironment is a major determinant of the beneficial or detrimental effects of MSCs and that the time window of administration is an important factor when initiating MSC therapy in patients with ARDS [73]. In their study, MSCs
were shown to aggravate acid-induced lung damage related to pulmonary fibrosis in the lung microenvironment, in which high levels of IL-6 and fibronectin were observed. Notably, modulation of the lung microenvironment with glutathione peroxidase-1 could reverse the deleterious effects of MSCs [73]. However, the lung tissues in different parts had diverse pathological changes due to the heterogeneity of ARDS. Consequently, determining the optimal local microenvironment and the ideal time window for MSC transplantation requires further research.

ARDS is a heterogeneous syndrome resulting from various aetiologies. A latent class analysis with data from two randomized controlled trials confirmed the presence of two ARDS subphenotypes, one of which was characterized by higher plasma levels of inflammatory biomarkers [84]. Response to treatment with positive end-expiratory pressure and fluid management strategies differed on the basis of subphenotype [84, 85]. H1N1 influenza-mediated lung injury in mice was unresponsive to MSC therapy [86]; however, MSCs markedly attenuated the injury of the alveolar-capillary membrane barrier in the more inflammatory H5N1-infected mice and improved their likelihood of survival [87]. In theory, ARDS patients with a hyperinflammatory phenotype are more likely to benefit from MSC therapy. In future clinical trials, identification and selection of populations with hyperinflammatory endotypes might be crucial for effective MSC therapy in patients with ARDS.

25. Conclusion

MSC-based therapy offers great promise for the management of ARDS due to its anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic properties. However, the low mobilization of MSCs to the sites of injury and poor survival of transplanted MSCs in the harsh microenvironment are obstacles faced by clinical translation. In recent years, several strategies have been tested in preclinical models to improve the therapeutic efficacy of MSCs, including genetic manipulation, hypoxia preconditioning, and modulation of the lung microenvironment. Despite increasing evidence that these strategies significantly enhance the innate properties of MSCs, thereby enhancing tissue repair and restoring lung function, further researches are still needed before these strategies can be translated into clinical practices.

Conflicts of Interest

All authors declare no conflict of interest.

Acknowledgments

This work is financed by the National Natural Science Foundations of China (81800619).

References

[1] G. D. Rubenfeld, E. Caldwell, E. Peabody et al., “Incidence and outcomes of acute lung injury,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1685–1693, 2005.

[2] G. Bellani, J. G. Laffey, T. Pham et al., “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries,” JAMA, vol. 315, no. 8, pp. 788–800, 2016.

[3] E. Gupta, M. D. Jacobs, G. George, and J. Roman, “Beyond the ICU: frailty and post-ICU disability. Healthcare use after acute respiratory distress syndrome and severe sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 199, no. 8, pp. 1028–1030, 2019.

[4] Acute Respiratory Distress Syndrome Network, R. G. Brower, M. A. Matthay et al., “Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome,” The New England Journal of Medicine, vol. 342, no. 18, pp. 1301–1308, 2000.

[5] C. Guérin, J. Reignier, J. C. Richard et al., “Prone positioning in severe acute respiratory distress syndrome,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2159–2168, 2013.

[6] G. F. Curley, J. G. Laffey, H. Zhang, and A. S. Slutsky, “Biotrauma and ventilator-induced lung injury: clinical implications,” Chest, vol. 150, no. 5, pp. 1109–1117, 2016.

[7] R. K. Albert, B. Smith, C. E. Perlman, and D. A. Schwartz, “Is progression of pulmonary fibrosis due to ventilation-induced lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 200, no. 2, pp. 140–151, 2019.

[8] M. Schmidt, G. Francineau, and A. Combes, “Recent advances in venovenous extracorporeal membrane oxygenation for severe acute respiratory distress syndrome,” Current Opinion in Critical Care, vol. 25, no. 1, pp. 71–76, 2019.

[9] A. Combes, A. Pesenti, and V. M. Ranieri, “Fifty years of research in ARDS. Is extracorporeal circulation the future of acute respiratory distress syndrome management,” American Journal of Respiratory and Critical Care Medicine, vol. 195, no. 9, pp. 1161–1170, 2017.

[10] P. D. Sottile, D. Albers, and M. M. Moss, “Neuromuscular blockade is associated with the attenuation of biomarkers of epithelial and endothelial injury in patients with moderate-to-severe acute respiratory distress syndrome,” Critical Care, vol. 22, no. 1, p. 63, 2018.

[11] T. D. Shaw, D. F. McCauley, and C. M. O’Kane, “Emerging drugs for treating the acute respiratory distress syndrome,” Expert Opinion on Emerging Drugs, vol. 24, no. 1, pp. 29–41, 2019.

[12] S. Horie, C. Masterson, J. Devaney, and J. G. Laffey, “Stem cell therapy for acute respiratory distress syndrome: a promising future,” Current Opinion in Critical Care, vol. 22, no. 1, pp. 14–20, 2016.

[13] J. Walter, L. B. Ware, and M. A. Matthay, “Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis,” The Lancet Respiratory Medicine, vol. 2, no. 12, pp. 1016–1026, 2014.

[14] A. J. Friedenstein, J. F. Gorskaja, and N. N. Kulagina, “Fibroblast precursors in normal and irradiated mouse hematopoietic organs,” Experimental Hematology, vol. 4, no. 5, pp. 267–274, 1976.

[15] E. M. Horwitz, K. Le Blanc, M. Dominici et al., “Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement,” Cytotherapy, vol. 7, no. 5, pp. 393–395, 2005.

[16] M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement,” *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.

[17] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multipotential cells from human adipose tissue: implications for cell-based therapies,” *Tissue Engineering*, vol. 7, no. 2, pp. 211–228, 2001.

[18] C. Rosada, J. Justesen, D. Melwik, P. Ebbesen, and M. Kassem, “The human umbilical cord blood: a potential source for osteoblast progenitor cells,” *Calcified Tissue International*, vol. 72, no. 2, pp. 135–142, 2003.

[19] S. H. Mei, C. C. Dos Santos, and D. J. Stewart, “Advances in stem cell and cell-based gene therapy approaches for experimental acute lung injury: a review of preclinical studies,” *Human Gene Therapy*, vol. 27, no. 10, pp. 802–812, 2016.

[20] J. Wagner, T. Kean, R. Young, J. E. Dennis, and A. I. Caplan, “Optimizing mesenchymal stem cell-based therapeutics,” *Current Opinion in Biotechnology*, vol. 20, no. 5, pp. 531–536, 2009.

[21] D. C. de Almeida, C. Donizetti-Oliveira, P. Barbosa-Costa, C. S. T. Origassa, and N. O. S. Câmara, “In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury,” *Clinical Biochemist Reviews*, vol. 34, no. 3, pp. 131–144, 2013.

[22] J. W. Lee, X. Fang, A. Krasnodembskaya, J. P. Howard, and M. A. Matthy, "Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors," *Stem Cells*, vol. 29, no. 6, pp. 913–919, 2011.

[23] S. Meirelles Lda, A. M. Fontes, D. T. Covas, and A. I. Caplan, “Mechanisms involved in the therapeutic properties of mesenchymal stem cells,” *Cytokine & Growth Factor Reviews*, vol. 20, no. 5–6, pp. 419–427, 2009.

[24] É. J. Bassi, D. C. de Almeida, P. M. M. Moraes-Vieira, and N. O. S. Câmara, “Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells,” *Stem Cell Reviews*, vol. 8, no. 2, pp. 329–342, 2012.

[25] K. Németh, A. Leelahavanichkul, P. S. Yuen et al., “Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production,” *Nature Medicine*, vol. 15, no. 1, pp. 42–49, 2009.

[26] M. N. Islam, S. R. Das, M. T. Emin et al., “Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury,” *Nature Medicine*, vol. 18, no. 5, pp. 759–765, 2012.

[27] G. Zheng, L. Huang, H. Tong et al., “Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study,” *Respiratory Research*, vol. 15, no. 1, p. 39, 2014.

[28] J. G. Wilson, K. D. Liu, H. Zhuo et al., “Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial,” *The Lancet Respiratory Medicine*, vol. 3, no. 1, pp. 24–32, 2015.

[29] O. E. Simonson, D. Mougiaiakos, N. Heldring et al., “In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome,” *Stem Cells Translational Medicine*, vol. 4, no. 10, pp. 1199–1213, 2015.

[30] M. A. Matthy, C. S. Calfee, H. Zhuo et al., “Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial,” *The Lancet Respiratory Medicine*, vol. 7, no. 2, pp. 154–162, 2019.

[31] J. X. Yang, N. Zhang, H. W. Wang, P. Gao, Q. P. Yang, and Q. P. Wen, “CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats,” *The Journal of Biological Chemistry*, vol. 290, no. 4, pp. 1994–2006, 2015.

[32] X. Lu, J. Han, X. Xu et al., “PGE2 promotes the migration of mesenchymal stem cells through the activation of FAK and ERK1/2 pathway,” *Stem Cells International*, vol. 2017, Article ID 8178643, 11 pages, 2017.

[33] J. Han, L. Zou, X. Xu, and H. Qiu, “E-Prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury,” *Human Gene Therapy*, vol. 27, no. 8, pp. 621–630, 2016.

[34] X. Chen, Y. Zhang, W. Wang, Z. Liu, J. Meng, and Z. Han, “Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharide-induced inflammatory and oxidative damage in pulmonary microvascular endothelial cells,” *Cellular Physiology and Biochemistry*, vol. 49, no. 1, pp. 101–122, 2018.

[35] X. Chen, S. Wu, L. Tang et al., “Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats,” *Journal of Cellular Physiology*, vol. 234, no. 5, pp. 7301–7319, 2019.

[36] Y. Imai, K. Kuba, and J. M. Penninger, “Angiotensin-conveting enzyme 2 in acute respiratory distress syndrome,” *Cellular and Molecular Life Sciences*, vol. 64, no. 15, pp. 2006–2012, 2007.

[37] X. Li, M. Molina-Molina, A. Abdul-Hafez, V. Uhal, A. Xaubet, and B. D. Uhal, “Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis,” *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 295, no. 1, pp. L178–L185, 2008.

[38] H. L. He, L. Liu, Q. H. Chen et al., “MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS,” *Journal of Cellular Physiology*, vol. 230, no. 3, pp. 691–701, 2015.

[39] H. He, L. Liu, Q. Chen et al., “Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury,” *Cell Transplantation*, vol. 24, no. 9, pp. 1699–1715, 2015.

[40] F. Min, F. Gao, Q. Li, and Z. Liu, “Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury,” *Molecular Medicine Reports*, vol. 11, no. 4, pp. 2387–2396, 2015.

[41] X. P. Cao, D. M. Han, L. Zhao et al., “Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury,” *Human Gene Therapy*, vol. 24, no. 3, pp. 343–353, 2013.

[42] S. Fukuhara, K. Sako, K. Noda, J. Zhang, M. Minami, and N. Mochizuki, “Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis,” *Histology and Histopathology*, vol. 25, no. 3, pp. 387–396, 2010.
lungs injury in mice by mesenchymal stem cells overexpressing angiopoietin-1,” PLoS Medicine, vol. 4, no. 9, p. e269, 2007.

[45] J. Xu, J. Qu, L. Cao et al., “Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice,” The Journal of Pathology, vol. 214, no. 4, pp. 472–481, 2008.

[46] M. J. Sweet, B. P. Leung, D. Kang et al., “A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of toll-like receptor 4 expression,” Journal of Immunology, vol. 166, no. 11, pp. 6633–6639, 2001.

[47] I. Martínez-González, O. Roca, J. R. Mascles et al., “Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 4, pp. 552–562, 2013.

[48] R. Kapur, M. Kim, R. Aslam et al., “T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10,” Blood, vol. 129, no. 18, pp. 2557–2569, 2017.

[49] C. Wang, D. Ly, X. Zhang, Z. A. Ni, X. Sun, and C. Zhu, “Interleukin-10-overexpressing mesenchymal stromal cells induce a series of regulatory effects in the inflammatory system and promote the survival of endotoxin-induced acute lung injury in mice model,” DNA and Cell Biology, vol. 37, no. 1, pp. 53–61, 2018.

[50] M. W. Epperly, H. L. Guo, M. Jefferson et al., “Cell phenotype specific kinetics of expression of intratracheally injected manganese superoxide dismutase-plasmid/liposomes (MnSOD-PL) during lung radioprotective gene therapy,” Gene Therapy, vol. 10, no. 2, pp. 163–171, 2003.

[51] H. X. Chen, H. Xiang, W. H. Xu et al., “Manganese superoxide dismutase gene-modified mesenchymal stem cells attenuate acute radiation-induced lung injury,” Human Gene Therapy, vol. 28, no. 6, pp. 523–532, 2017.

[52] P. W. Finch and J. S. Rubin, “Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair,” Advances in Cancer Research, vol. 91, pp. 69–136, 2004.

[53] P. Ray, “Protection of epithelial cells by keratinocyte growth factor signaling,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 221–225, 2005.

[54] J. Chen, C. Li, X. Gao et al., “Keratinocyte growth factor gene delivery via mesenchymal stem cells protects against lipopolysaccharide-induced acute lung injury in mice,” PLoS One, vol. 8, no. 12, p. e83303, 2013.

[55] E. Y. Choi, E. Chavakis, M. A. Czabanke et al., “Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment,” Science, vol. 322, no. 5904, pp. 1101–1104, 2008.

[56] Y. F. Zhao, W. Xiong, and X. L. Wu, “Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice,” Molecular Medicine Reports, vol. 9, no. 5, pp. 1583–1589, 2014.

[57] S. Hacein-Bey-Abina, A. Garrigue, G. P. Wang et al., “Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1,” The Journal of Clinical Investigation, vol. 118, no. 9, pp. 3132–3142, 2008.

[58] S. Nayak and R. W. Herzog, “Progress and prospects: immune responses to viral vectors,” Gene Therapy, vol. 17, no. 3, pp. 295–304, 2010.
D. Islam, Y. Huang, V. Fanelli et al., "Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 199, no. 10, pp. 1214–1224, 2019.

M. L. Bustos, L. Huleihel, E. M. Meyer et al., "Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels," *Stem Cells Translational Medicine*, vol. 2, no. 11, pp. 884–895, 2013.

Q. Wang, H. Zhu, W. G. Zhou et al., "N-Acetylcysteine-pre-treated human embryonic mesenchymal stem cell administration protects against bleomycin-induced lung injury," *The American Journal of the Medical Sciences*, vol. 346, no. 2, pp. 113–122, 2013.

D. Li, Q. Liu, L. Qi, X. Dai, H. Liu, and Y. Wang, "Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury," *Molecular Medicine Reports*, vol. 14, no. 2, pp. 1681–1692, 2016.

Y. Petrenko, E. Syková, and Š. Kubinová, “The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids,” *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 94, 2017.

T. J. Bartosh, J. H. Ylöstalo, A. Mohammadipoor et al., “Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 31, pp. 13724–13729, 2010.

N. C. Cheng, S. Y. Chen, J. R. Li, and T. H. Young, “Short-term spheroid formation enhances the regenerative capacity of adipose-derived stem cells by promoting stemness, angiogenesis, and chemotaxis,” *Stem Cells Translational Medicine*, vol. 2, no. 8, pp. 584–594, 2013.

D. Shinmura, I. Togashi, S. Miyoshi et al., “Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function," *Stem Cells*, vol. 29, no. 2, pp. 357–366, 2011.

Z. Yang, J. Concannon, K. S. Ng et al., “Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation," *Scientific Reports*, vol. 6, no. 1, 2016.

K. A. Lee, W. Shim, M. J. Paik et al., “Analysis of changes in the viability and gene expression profiles of human mesenchymal stromal cells over time," *Cytotherapy*, vol. 11, no. 6, pp. 688–697, 2009.

M. L. Bustos, L. Huleihel, M. G. Kapetanaki et al., “Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response," *American Journal of Respiratory and Critical Care Medicine*, vol. 189, no. 7, pp. 787–798, 2014.

C. S. Calfee, K. Delucchi, P. E. Parsons et al., "Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials," *The Lancet Respiratory Medicine*, vol. 2, no. 8, pp. 611–620, 2014.

K. R. Famous, K. Delucchi, L. B. Ware et al., “Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy," *American Journal of Respiratory and Critical Care Medicine*, vol. 195, no. 3, pp. 331–338, 2017.